Welcome to the Addiction Awareness Scales
The addiction awareness scales measure the core dimensions of clinical insight in addictive disorders, including general illness awareness, symptom attribution, awareness of need for treatment, and awareness of negative consequences attributable to the illness. The addiction awareness scales were designed to assess clinical insight in addictive disorders, including alcohol (AAS©), nicotine (NAS©), gambling (GAS©), and other substances (SAS©).
The AAS©, SAS©, NAS©, and GAS© scales are the first illness awareness scales in addiction. The 7-item self-report scales are easy to complete and can be done in less than 2 minutes. These addiction awareness scales show good internal consistency, reliability and validity. Using a 10-point Likert scale for each item, the addiction awareness scales have the capacity to detect small, temporally sensitive changes in insight.
The AAS©, SAS©, NAS©, and GAS© scales are available for download. You must agree to the terms of use.
Terms of Use
AAS©, SAS©, NAS©, and GAS© scales are owned by the Centre for Addiction & Mental Health (CAMH), Toronto, Canada, published 2020 (Canadian Copyright Registration No. 1174237, No.1174234, No. 1174238, No. 1174236; Registered September 24, 2020).
Please read the content below and click the 'Accept and Continue' button to acknowledge the terms and usage of the Illness Awareness Scales and the related addiction awareness scales. Thank you for your interest and support.
Permission to use
Permission to use the Illness Awareness Scales and the related AAS©, SAS©, NAS©, and GAS© scales are as follows.
Clinical Use
- Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed WITHOUT permission subject to the exception below for entities funded by a commercial entity or pharma. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma. - Commercial Entity/Pharma
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.
Educational Use
- Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed WITHOUT permission subject to the exception below for entities funded by a commercial entity or pharma. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma. - Commercial Entity/Pharma
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.
Research Use
- Universities/Foundations/HealthProfessionals/Hospitals/Clinics/Public Health Institutes
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed only WITH prior written permission from CAMH. The test should be made available free of charge to patients. Written permission from CAMH and Licensing Agreement with CAMH is required if funded by a commercial entity or pharma. - Commercial Entity/Pharma sponsored research
AAS©, SAS©, NAS©, and GAS© scales may be used, reproduced, and distributed only WITH prior written permission from CAMH and Licensing Agreement with CAMH. The test should be made available free of charge to patients.
Agreement to Terms of Use
Click the button to accept and agree to terms of use.
For AAS: Alcohol Use Awareness and Insight Scale
Accept and continue to AAS
For SAS: Substance Use Awareness and Insight Scale
Accept and continue to SAS
For NAS: Nicotine Awareness and Insight Scale
Accept and continue to NAS
For GAS: Gambling Awareness and Insight Scale
Accept and continue to GAS
More information about the tools
For more information, please contact:
- Dr. Philip Gerretsen, MD, PhD, FRCP